ArticleInternational journal of colorectal disease2025
Evaluation of the relation of CD133 expression measured by immunohistochemistry assay with the survival of the colorectal cancer patients: a retrospective cohort study.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a prevalent and deadly malignancy, often characterized by cellular heterogeneity and resistance to therapy. CD133, a proposed cancer stem cell marker, has been implicated in poor clinical outcomes, but its prognostic value remains controversial, particularly in diverse populations.
objectiveThis study aimed to evaluate the relationship between CD133 expression and overall survival (OS) in patients with colorectal adenocarcinoma treated at Mousavi Hospital in Zanjan, Iran.
methodsThis retrospective cohort study analyzed 55 patients who underwent surgical resection for histologically confirmed colorectal adenocarcinoma between 2012 and 2017. CD133 expression was assessed using immunohistochemistry (IHC) and categorized as positive or negative. Associations with clinicopathological features and 5-year survival were examined using logistic regression and Cox proportional hazards (PH) models.
resultsCD133 expression was detected in 47.3% of tumors. It was significantly more prevalent in high-grade tumors (83.1% vs 18.7%, p = 0.001) and in female patients (66.7% vs 32.2%, p = 0.015). Five-year survival was significantly lower in CD133-positive patients (19.2%) compared to CD133-negative individuals (75.9%, p < 0.001). In multivariable Cox regression adjusted for tumor grade and age, CD133 positivity was associated with increased hazard of death (adjusted hazard ratio(HR) = 5.03; 95% confidence interval (CI) 1.66-15.25; p = 0.004). Because of the modest sample size and wide confidence intervals, this association should be considered preliminary. In crude analyses, tumor grade impacted survival; in the adjusted model, only CD133 remained remarkable, while age, sex, and tumor location showed no significant associations.
conclusionsCD133 expression is significantly associated with high tumor grade and poor survival in Iranian CRC patients, but findings should be interpreted with caution, given the small cohort. Its evaluation could aid in identifying high-risk individuals and guiding personalized treatment strategies in larger confirmatory studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.